"Pyrrolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed)
| Descriptor ID |
D011760
|
| MeSH Number(s) |
D03.383.773.812
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidinones".
This graph shows the total number of publications written about "Pyrrolidinones" by people in this website by year, and whether "Pyrrolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 3 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 1 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrrolidinones" by people in Profiles.
-
HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H. J Antimicrob Chemother. 2022 09 30; 77(10):2793-2802.
-
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2021 10; 88(4):643-654.
-
Gamma-Butyrolactone Overdose Potentially Complicated by Co-Ingestion of Industrial Solvent N-Methyl-2-Pyrrolidone. J Anal Toxicol. 2021 Mar 12; 45(3):322-324.
-
The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues. Molecules. 2019 Jul 09; 24(13).
-
Serum Metabolomics and Incidence of Atrial Fibrillation (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019 06 15; 123(12):1955-1961.
-
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019 05; 156(6):1849-1861.e13.
-
Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
-
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Cancer Invest. 2017 Aug 09; 35(7):463-472.
-
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64(11).
-
?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem. 2017 06 16; 292(24):9967-9974.